<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2047">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134519</url>
  </required_header>
  <id_info>
    <org_study_id>XJLL-KY20212136</org_study_id>
    <nct_id>NCT05134519</nct_id>
  </id_info>
  <brief_title>RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer</brief_title>
  <official_title>Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Coupling Agent (RC48-ADC) for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression (Seraph)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm exploratory study to explore the effect of RC48 in HER2-positive&#xD;
      neoadjuvant therapy and evaluate the non-inferiority of RC48 by comparing the latest reported&#xD;
      data of T-DM1 in neoadjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-arm exploratory study was conducted in 20 patients with HER2-positive breast cancer&#xD;
      to explore the effect of RC48 in HER2-positive neoadjuvant therapy (treatment regimen:&#xD;
      RC482.0 mg/kg, intravenous drip, once every 2 weeks). After 4-6 cycles, surgery was performed&#xD;
      to evaluate the effect of neoadjuvant chemotherapy. The latest reported data of T-DM1 in&#xD;
      neoadjuvant therapy were compared to evaluate the non-inferiority of RC48.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 26, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 14 days)</time_frame>
    <description>absence of invasive carcinoma in the breast and axillary lymph nodes, while residual ductal carcinoma in situ was accepted (ypT0orTisypN0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>during the period of neadjuvant chemotherapy</time_frame>
    <description>Serious adverse effect occur within neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>RC48 for neadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC48-ADC: 2.0 mg/kg, IV drip, Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)</intervention_name>
    <description>Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles</description>
    <arm_group_label>RC48 for neadjuvant chemotherapy</arm_group_label>
    <other_name>RC48</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Enrolled were ≥ 18 years of age and &lt; 80 years of age&#xD;
&#xD;
          2. Female or male breast cancer&#xD;
&#xD;
          3. Patients with early or locally advanced breast cancer who are HER2-positive, have a&#xD;
             tumor larger than 2 cm and/or have lymph node metastasis: HER2-positive is defined as&#xD;
             3 + by immunohistochemistry, or 2 + by immunohistochemistry, with a positive FISH&#xD;
             test.&#xD;
&#xD;
          4. Left ventricular score ≥ 55%&#xD;
&#xD;
          5. ECOGPS score 0 or 1&#xD;
&#xD;
          6. Able to understand the test requirements, willing and able to comply with the test and&#xD;
             follow-up procedures&#xD;
&#xD;
          7. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. cardiac, hepatic, renal, or psychiatric disease history&#xD;
&#xD;
          2. History of other malignancy within the last 5 years, with the exception of adequately&#xD;
             treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the&#xD;
             cervix.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

